Activated *H-ras* gene mutations in transitional cell carcinoma of urinary bladder in a Kashmiri population

Arshad Ahmad Pandith1, Zafar Shah1, Roohi Rasool1, Dil-Afroze1, Adfar Yousof2, Nighat Parveen2, Saleem Wani3, and Mushtaq Siddiqi1

Departments of 1Immunology and Molecular Medicine, 2Clinical Biochemistry, and 3Urology, Sher-i-Kashmir Institute of Medical Sciences, Sura, Srinagar, Kashmir, India

ABSTRACT

Aims and background. The primary aim of the study was to evaluate the incidence of *H-ras* specific point mutations among a group of Kashmiri patients diagnosed with bladder cancer. We also explored the correlation of clinic-pathological status of the illness with these mutations.

Methods and study design. The DNA samples of both tumor and normal tissue were evaluated for the occurrence of *H-ras* activating mutations in exon 1 and 2 by PCR-SCCP and DNA sequencing. In addition, blood was also collected from all the cases to rule out any germ-line mutation.

Results. Point mutations of activated *H-ras* identified in bladder cancer patients were 14.5% (7 of 48), including four transversions (two G→T and two A→T) and three transitions (A→G). Of the mutations, 71.4% were detected in codon 61 and 28.6% in codon 12. The pattern of mutation in the study showed a significant association with smoking in bladder tumors (*P*<0.05). No correlation was found between tumor grade and/or stage and the presence of *H-ras* mutation.

Conclusions. Activation of *H-ras* by mutation plays a less frequent role than other genetic events in the development of the most transitional cell tumors of the bladder in Kashmiri population. Free full text available at www.tumorionline.it